Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;23(3):287-300.
doi: 10.1007/s40257-021-00669-6. Epub 2022 Mar 8.

Economic Burden of Chronic Hand Eczema: A Review

Affiliations
Review

Economic Burden of Chronic Hand Eczema: A Review

April Armstrong et al. Am J Clin Dermatol. 2022 May.

Abstract

There has been no extensive synthesis of studies evaluating the cost of chronic hand eczema (CHE). This review evaluated the societal costs, healthcare resource utilisation, missed work time and job loss due to CHE. MEDLINE and 16 other databases and websites were searched in October 2020 for studies meeting prespecified inclusion criteria. Studies conducted in Europe, Australia, New Zealand or the Americas were included. Two reviewers independently assessed titles and abstracts, and full-text papers published in English between 2000 and 2020, for relevance. Data extraction was carried out by one reviewer and checked by a second reviewer. All data were based on costs between 2001 and 2013 but have been inflated to 2020 prices and converted to US dollars and Euros. A total of 30 studies (reported in 33 publications) were included in the synthesis. Mean total societal costs per year per patient ranged from $2549 (€1813) to $10,883 (€7738). Pharmacological therapy was, on average, $28.34 (€20.15) per month in Italy and $36.49 (€25.94) per month for emollients in Switzerland. Yearly treatment costs were $599.05 (€425.92) for drugs, including topical corticosteroids, topical calcineurin inhibitors, other topical treatments and oral treatments, and $178.40 for emollients, in Germany. CHE was associated with hospitalisation costs ranging from $81.86 (€58.20) per patient per month (US) to $105.04 (€74.68) per patient per month (Italy) and $639.59 (€454.75) per year (Germany). Up to 57% of patients took sick leave and up to 25% reported job loss/job change due to CHE. This review confirms the significant cost burden of CHE. Given the paucity of studies estimating the monetary costs of absenteeism, presenteeism and job loss associated with CHE, current mean societal costs are likely underestimated. Uncontrolled disease may also lead to increased costs to patients and society.

PubMed Disclaimer

Conflict of interest statement

Jacob Thyssen has been an advisor/investigator or speaker for Abbvie, Pfizer, LEO Pharma, Regeneron, Sanofi Genzyme and Eli Lilly & Co. Julie Hahn-Pedersen is a former employee of LEO Pharma, who sponsored this review. Chris Bartlett (and formerly, Julie Glanville) is employed by York Health Economics Consortium, which received funding from LEO Pharma to conduct this review. April Armstrong has served as a research investigator or consultant to AbbVie, ASLAN, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and Modmed.

Figures

Fig. 1
Fig. 1
PRISMA diagram of record selection process. PRISMA preferred reporting items for systematic reviews and meta-analyses

References

    1. Politiek K, Oosterhaven JAF, Vermeulen KM, Schuttelaar M-LA. Systematic review of cost-of-illness studies in hand eczema. Contact Derm. 2016;75(2):67–76. doi: 10.1111/cod.12590. - DOI - PubMed
    1. Capucci S, Hahn-Pedersen J, Vilsboll A, Kragh N. Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis. 2020;31(3):178–184. doi: 10.1097/DER.0000000000000598. - DOI - PubMed
    1. Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):4–12. doi: 10.1111/jdv.16061. - DOI - PubMed
    1. Meding B, Wrangsjo K, Jarvholm B. Fifteen-year follow-up of hand eczema: persistence and consequences. Br J Dermatol. 2005;152(5):975–980. doi: 10.1111/j.1365-2133.2005.06494.x. - DOI - PubMed
    1. Mollerup A, Veien NK, Johansen JD. Chronic hand eczema—self-management and prognosis: a study protocol for a randomised clinical trial. BMC Dermatol. 2012;12:6. doi: 10.1186/1471-5945-12-6. - DOI - PMC - PubMed